1. Scrip
  2. >>Business

After An Upbeat J.P. Morgan, Three Biopharmas Look To Kick Off IPOs For 2024

 
• By Andrew McConaghie

Gene editing company Metagenomi and two oncology biopharmas will test the IPO waters soon – with hopes this could pave the way for others.

Share price movement
• Source: Shutterstock

2023 was another tough year for biotech initial public offerings, but there are some signs that 2024 could see the market open up again. After a more upbeat mood at the J.P. Morgan conference (JPM) and signs of improving macro-economic stability, the next big test for biotech is a trio of planned flotations. These will come from gene-editing specialist Metagenomi and cancer-focused start-ups ArriVent Biopharma and CG Oncology.

Key Takeaways

  • After two tough years for early-stage biotech, there are signs IPOs and other funding could revive in 2024

All three IPO filings were made ahead of the annual San Francisco investor conference which took place this week, but...

More from Business

More from Scrip

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial